228 related articles for article (PubMed ID: 24828664)
41. Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer.
Park KS; Kim HK; Lee JH; Choi YB; Park SY; Yang SH; Kim SY; Hong KM
J Cancer Res Clin Oncol; 2010 Apr; 136(4):493-502. PubMed ID: 19763620
[TBL] [Abstract][Full Text] [Related]
42. LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma.
Xu Y; Li Y; Jin J; Han G; Sun C; Pizzi MP; Huo L; Scott A; Wang Y; Ma L; Lee JH; Bhutani MS; Weston B; Vellano C; Yang L; Lin C; Kim Y; MacLeod AR; Wang L; Wang Z; Song S; Ajani JA
Mol Cancer; 2019 Oct; 18(1):141. PubMed ID: 31601234
[TBL] [Abstract][Full Text] [Related]
43. microRNA 125a Regulates MHC-I Expression on Esophageal Adenocarcinoma Cells, Associated With Suppression of Antitumor Immune Response and Poor Outcomes of Patients.
Mari L; Hoefnagel SJM; Zito D; van de Meent M; van Endert P; Calpe S; Sancho Serra MDC; Heemskerk MHM; van Laarhoven HWM; Hulshof MCCM; Gisbertz SS; Medema JP; van Berge Henegouwen MI; Meijer SL; Bergman JJGHM; Milano F; Krishnadath KK
Gastroenterology; 2018 Sep; 155(3):784-798. PubMed ID: 29885883
[TBL] [Abstract][Full Text] [Related]
44. Loss of Bcl-2 expression in Barrett's dysplasia and adenocarcinoma is associated with tumor progression and worse survival but not with response to neoadjuvant chemoradiation.
Raouf AA; Evoy DA; Carton E; Mulligan E; Griffin MM; Reynolds JV
Dis Esophagus; 2003; 16(1):17-23. PubMed ID: 12581249
[TBL] [Abstract][Full Text] [Related]
45. Amplification of transglutaminase 2 enhances tumor-promoting inflammation in gastric cancers.
Cho SY; Oh Y; Jeong EM; Park S; Lee D; Wang X; Zeng Q; Qin H; Hu F; Gong H; Liu X; Zhang G; Na D; Lee J; Chae J; Suh YS; Kong SH; Lee HJ; Kim JI; Park H; Zhang C; Yang HK; Lee C
Exp Mol Med; 2020 May; 52(5):854-864. PubMed ID: 32467608
[TBL] [Abstract][Full Text] [Related]
46. Identification of Fn14/TWEAK receptor as a potential therapeutic target in esophageal adenocarcinoma.
Watts GS; Tran NL; Berens ME; Bhattacharyya AK; Nelson MA; Montgomery EA; Sampliner RE
Int J Cancer; 2007 Nov; 121(10):2132-9. PubMed ID: 17594693
[TBL] [Abstract][Full Text] [Related]
47. Transglutaminase 2 Regulates Self-renewal and Stem Cell Marker of Human Colorectal Cancer Stem Cells.
Kang S; Oh SC; Min BW; Lee DH
Anticancer Res; 2018 Feb; 38(2):787-794. PubMed ID: 29374703
[TBL] [Abstract][Full Text] [Related]
48. Association of pretherapeutic expression of chemotherapy-related genes with response to neoadjuvant chemotherapy in Barrett carcinoma.
Langer R; Specht K; Becker K; Ewald P; Bekesch M; Sarbia M; Busch R; Feith M; Stein HJ; Siewert JR; Höfler H
Clin Cancer Res; 2005 Oct; 11(20):7462-9. PubMed ID: 16243820
[TBL] [Abstract][Full Text] [Related]
49. IGFBP-3 and IGFBP-10 (CYR61) up-regulation during the development of Barrett's oesophagus and associated oesophageal adenocarcinoma: potential biomarkers of disease risk.
Di Martino E; Wild CP; Rotimi O; Darnton JS; Olliver RJ; Hardie LJ
Biomarkers; 2006; 11(6):547-61. PubMed ID: 17056474
[TBL] [Abstract][Full Text] [Related]
50. Deciphering the unique microRNA signature in human esophageal adenocarcinoma.
Saad R; Chen Z; Zhu S; Jia P; Zhao Z; Washington MK; Belkhiri A; El-Rifai W
PLoS One; 2013; 8(5):e64463. PubMed ID: 23724052
[TBL] [Abstract][Full Text] [Related]
51. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas.
Yoon HH; Shi Q; Sukov WR; Wiktor AE; Khan M; Sattler CA; Grothey A; Wu TT; Diasio RB; Jenkins RB; Sinicrope FA
Clin Cancer Res; 2012 Jan; 18(2):546-54. PubMed ID: 22252257
[TBL] [Abstract][Full Text] [Related]
52. The miR-106b-25 polycistron, activated by genomic amplification, functions as an oncogene by suppressing p21 and Bim.
Kan T; Sato F; Ito T; Matsumura N; David S; Cheng Y; Agarwal R; Paun BC; Jin Z; Olaru AV; Selaru FM; Hamilton JP; Yang J; Abraham JM; Mori Y; Meltzer SJ
Gastroenterology; 2009 May; 136(5):1689-700. PubMed ID: 19422085
[TBL] [Abstract][Full Text] [Related]
53. Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma.
Lord RV; Brabender J; Wickramasinghe K; DeMeester SR; Holscher A; Schneider PM; Danenberg PV; DeMeester TR
Surgery; 2005 Nov; 138(5):924-31. PubMed ID: 16291394
[TBL] [Abstract][Full Text] [Related]
54. TGM2 inhibition attenuates ID1 expression in CD44-high glioma-initiating cells.
Fu J; Yang QY; Sai K; Chen FR; Pang JC; Ng HK; Kwan AL; Chen ZP
Neuro Oncol; 2013 Oct; 15(10):1353-65. PubMed ID: 23877317
[TBL] [Abstract][Full Text] [Related]
55. Hypermethylation of the nel-like 1 gene is a common and early event and is associated with poor prognosis in early-stage esophageal adenocarcinoma.
Jin Z; Mori Y; Yang J; Sato F; Ito T; Cheng Y; Paun B; Hamilton JP; Kan T; Olaru A; David S; Agarwal R; Abraham JM; Beer D; Montgomery E; Meltzer SJ
Oncogene; 2007 Sep; 26(43):6332-40. PubMed ID: 17452981
[TBL] [Abstract][Full Text] [Related]
56. Genes of the interleukin-18 pathway are associated with susceptibility to Barrett's esophagus and esophageal adenocarcinoma.
Babar M; Ryan AW; Anderson LA; Segurado R; Turner G; Murray LJ; Murphy SJ; Johnston BT; Comber H; Reynolds JV; McManus R
Am J Gastroenterol; 2012 Sep; 107(9):1331-41. PubMed ID: 22664470
[TBL] [Abstract][Full Text] [Related]
57. Overexpression of CD55 from Barrett's esophagus is associated with esophageal adenocarcinoma risk.
Murao T; Shiotani A; Fujita Y; Yamanaka Y; Kamada T; Manabe N; Hata J; Nishio K; Haruma K
J Gastroenterol Hepatol; 2016 Jan; 31(1):99-106. PubMed ID: 26202380
[TBL] [Abstract][Full Text] [Related]
58. MicroRNA Expression Signatures During Malignant Progression From Barrett's Esophagus.
Bansal A; Gupta V; Wang K
J Cell Biochem; 2016 Jun; 117(6):1288-95. PubMed ID: 26808728
[TBL] [Abstract][Full Text] [Related]
59. Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma.
Wagener-Ryczek S; Schoemmel M; Kraemer M; Bruns C; Schroeder W; Zander T; Gebauer F; Alakus H; Merkelbach-Bruse S; Buettner R; Loeser H; Thelen M; Schlößer HA; Quaas A
Cancer Immunol Immunother; 2020 Apr; 69(4):523-533. PubMed ID: 31960110
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of miR-21 and miR-375 as prognostic biomarkers in esophageal cancer.
Winther M; Alsner J; Tramm T; Baeksgaard L; Holtved E; Nordsmark M
Acta Oncol; 2015; 54(9):1582-91. PubMed ID: 26481465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
